Responses in the brain to an experimental lung cancer drug lasted a median 9.7 months.
Taiho Oncology and Cullinan Therapeutics (CGEM) reported that zipalertinib, an experimental lung cancer drug, showed clinically meaningful intracranial antitumor activity in a Phase 2b trial. Among 43 patients, it achieved a 67.4% intracranial objective response rate. The drug is being evaluated for NSCLC with EGFR mutations and active CNS metastases. Results will be presented at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
Positive trial data could catalyze share price appreciation for CGEM and increase investor interest in EGFR-targeted therapies.
Market read
New clinical data for a niche lung cancer drug may affect biotech valuations and inform pipeline expectations.
What to watch
Regulatory timelines and competition from other EGFR inhibitors could limit upside.
Background
The article reports first public disclosure of zipalertinib's Phase 2b intracranial activity results presented at ESMO 2026.
Ticker impact
Cullinan Therapeutics (NASDAQ: CGEM) is co-developing zipalertinib and announced positive Phase 2b intracranial activity data for EGFR ex20ins NSCLC.
upward pressure as investors price in potential future approvals and market opportunity.
The data are newly disclosed, clinically meaningful, and represent a key milestone for the company's pipeline.
Market effects
Strengthens the EGFR-mutant NSCLC therapeutic segment and may lift peer biotech stocks.
Primarily U.S. biotech market; limited immediate regional effect.
Highlights progress in targeted lung cancer therapies, relevant to global oncology investors.
Counterpoint
Data may not translate to commercial success; later-stage trials could reveal safety issues.
Key entities
- CompanyCullinan Therapeutics
Biopharma developing zipalertinib in partnership with Taiho Oncology.
- CompanyTaiho Oncology
Developer of zipalertinib, partner in the REZILIENT2 trial.
